NCT02633137 - Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 14, 2015

Primary Completion Date

November 7, 2023

Study Completion Date

November 7, 2023

Conditions

Mantle Cell LymphomaUntreated

Interventions

DRUG

Lenalidomide

DRUG

R-CHOP

"* Rituximab 375 mg/m\^2 IVPB with premedications Day 1~* Cyclophosphamide 750 mg/m\^2 IVPB Day 1~* Doxorubicin 50 mg/m\^2 IVP Day 1~* Vincristine 1.4 mg/m\^2 IVP (capped at 2 mg) Day 1~* Prednisone 100 mg PO Daily on Days 1-5 or 2-6"

DRUG

high-dose cytarabine (HIDAC)

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Commack, Commack

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale